Ascentage Pharma Group International (HKG:6855) raised $126.4 million from its US initial public offering of 7,325,000 American depository shares placed to at least six parties at $17.25 apiece, a Tuesday press release said.
The drug maker plans to use the net proceeds of $112.9 million for NDS approval for a drug and its launch in China, for clinical development of Olverembatinib in the United States and other countries, for research and development and for the development of the future pipeline programs of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.